At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 98 enrolled
Drug / intervention
LCZ696 +2 moredrug
Likely dose
LCZ696 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Parallel Group Study to Evaluate Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects
In Brief
A Phase 2 clinical trial evaluating LCZ696, amlodipine, and 1 other intervention for Hypertension and Concurrent Obesity. Completed, enrolled 98 participants across 3 sites in 2 countries.
Detailed Summary
This study investigated the effects of LCZ696 on insulin sensitivity, lipolysis, and oxidative metabolism in obese hypertensive subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, Concurrent Obesity
CountriesGermany, Netherlands
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartOct 2012
Primary CompletionJul 2013
TodayJul 2026
First PostedJun 29, 2012
Enrollment StartOct 1, 2012
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.0 years ago
Interventions
LCZ696drug
LCZ696 was provided as 400 mg tablets.
amlodipinedrug
amlodipine was provided as 5 mg tablets.
Placebodrug
Matching placebo to LCZ696 and amlodipine.